Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis

Neurology

Volumn 50, Issue 2, 1998, Pages 403-406

  Gasperini, Claudio ^a,b   Pozzilli, C ^c   Bastianello, S ^c   Koudriavtseva, T ^c   Galgani, S ^a   Millefiorini, E ^c   Paolillo, A ^c   Horsfield, M A ^c   Bozzao, L ^c   Fieschi, C ^c  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; METHYLPREDNISOLONE; RECOMBINANT BETA INTERFERON; STEROID;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0031911495     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.2.403     Document Type: Article

References (15)

1. Kermode AG, Thompson AJ, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113:1477-1489.
2. Bastianello S, Pozzilli C, Bernardi S, et al. Serial study of gadolinium DTPA MRI enhancement in multiple sclerosis. Neurology 1990;40:591-595.
3. Durelli L, Cocito D, Riccio A, et al. High dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations. Neurology 1989;36:238-243.
4. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39:969-971.
5. Barkhof F, Hommes OR, Sheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high dose intravenous methylprednisolone treatment in multiple sclerosis. Neurology 1991;41:1219-1222.
6. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-453.
7. Stone LA, Frank JA, Albert PS, et al. The effect of interferon beta on blood brain barrier disruption demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 1995;37:611-617.
8. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon beta 1a: a short term study in relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
9. Wicks D, Tofts PS, Miller DH, et al. Volume measurements of multiple sclerosis with magnetic resonance imaging. Neuroradiology 1992;34:475-479.
10. Loseff NA, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996;1:218-222.
11. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium-enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287.
12. Rosemberg GA, Dencoff JE, Correa N, et al. Effect of steroids on CSF matrix metalloproteinase in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
13. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
14. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta 1b decreases the migration of T lymphocytes in vitro: effect on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
15. Rudge P, Miller D, Crimlisik H, Thorpe J. Does Interferon beta cause initial exacerbation of multiple sclerosis? Lancet 1995;345:580.